Newron Pharmaceuticals
Market Cap
CHF105.8m
Last Updated
2019/09/17 20:59 UTC
Data Sources
Company Financials +
Executive Summary
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally.
Snowflake
Fundamentals
Exceptional growth potential with adequate balance sheet.
Share Price & News
How has Newron Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
6.5%
SWX:NWRN
0.9%
CH Pharmaceuticals
-0.08%
CH Market
1 Year Return
-33.0%
SWX:NWRN
11.1%
CH Pharmaceuticals
6.6%
CH Market
NWRN underperformed the Pharmaceuticals industry which returned 9.5% over the past year.
NWRN underperformed the Market in Switzerland which returned 6.1% over the past year.
Share holder returns
| NWRN | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.5% | 0.9% | -0.08% |
| 30 Day | 0.5% | 0.4% | 2.9% |
| 90 Day | -3.1% | -2.3% | 0.8% |
| 1 Year | -33.0%-33.0% | 21.1%11.1% | 12.2%6.6% |
| 3 Year | -73.0%-73.0% | 30.1%11.5% | 32.3%15.4% |
| 5 Year | -63.3%-63.3% | 23.3%-0.7% | 34.5%13.4% |
Price Volatility Vs. Market
How volatile is Newron Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
13 hours ago | Simply Wall St
These Fundamentals Make Newron Pharmaceuticals S.p.A. (VTX:NWRN) Truly Worth Looking At2 weeks ago | Simply Wall St
Is Newron Pharmaceuticals S.p.A. (VTX:NWRN) Excessively Paying Its CEO?1 month ago | Simply Wall St
Does Market Volatility Impact Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Share Price?Valuation
Is Newron Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?
>50%
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Newron Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
Newron Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
Price Based on Earnings
Newron Pharmaceuticals is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.
Newron Pharmaceuticals is loss making, we can't compare the value of its earnings to the Switzerland market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Newron Pharmaceuticals, we can't assess if its growth is good value.
Price Based on Value of Assets
Newron Pharmaceuticals is good value based on assets compared to the CH Pharmaceuticals industry average.
Next Steps
Future Growth
How is Newron Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?
71.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Newron Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Newron Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
Newron Pharmaceuticals's revenue growth is expected to exceed the Switzerland market average.
Newron Pharmaceuticals's earnings growth is expected to exceed the Switzerland market average.
Newron Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 3.3%.
Earnings per Share Growth Estimates
Future Return on Equity
Newron Pharmaceuticals is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
Next Steps
Past Performance
How has Newron Pharmaceuticals performed over the past 5 years?
-2.3%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Newron Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Newron Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Newron Pharmaceuticals's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Newron Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Newron Pharmaceuticals has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Newron Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Newron Pharmaceuticals's financial position?
Financial Position Analysis
Newron Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Newron Pharmaceuticals's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Newron Pharmaceuticals's level of debt (22.3%) compared to net worth is satisfactory (less than 40%).
The level of debt compared to net worth has increased over the past 5 years (3.7% vs 22.3% today).
Balance Sheet
Low level of unsold assets.
Debt is covered by short term assets, assets are 6.4x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Newron Pharmaceuticals has sufficient cash runway for 1.4 years based on current free cash flow.
Newron Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.2% each year.
Next Steps
Dividend
What is Newron Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Newron Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Newron Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Newron Pharmaceuticals has not reported any payouts.
Unable to verify if Newron Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Newron Pharmaceuticals has not reported any payouts.
Future Payout to Shareholders
No need to calculate the sustainability of Newron Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Switzerland.
Next Steps
Management
What is the CEO of Newron Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
7.3yrs
Average management tenure
CEO
Stefan Weber (54yo)
7.3yrs
Tenure
€647,000
Compensation
Mr. Stefan Weber serves as the Chief Financial Officer and Finances and Administration Director at Duktus S.A. Mr. Weber has been the Chief Executive Officer of Newron Pharmaceuticals SpA since June 1, 201 ...
CEO Compensation Analysis
Stefan's remuneration is about average for companies of similar size in Switzerland.
Stefan's compensation has increased whilst company is loss making.
Management Age and Tenure
7.3yrs
Average Tenure
62yo
Average Age
The average tenure for the Newron Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
7.0yrs
Average Tenure
62.5yo
Average Age
The tenure for the Newron Pharmaceuticals board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Stefan Weber (54yo)
CEO & Executive Director
- Tenure: 7.3yrs
- Compensation: €647.00k
Marco Caremi (62yo)
Executive Vice President of Business Development
- Tenure: 7.3yrs
Ravi Anand (62yo)
Chief Medical Officer
- Tenure: 14.3yrs
- Compensation: €1.07m
Dennis Dionne (69yo)
Vice President of Commercial Affairs
- Tenure: 4.7yrs
Roberto Galli
Vice President of Finance
- Tenure: 7.3yrs
Board Members
Patrick Langlois (74yo)
Non-Executive Director
- Tenure: 11.2yrs
- Compensation: €98.00k
Don deBethizy (69yo)
Non-Executive Director
- Tenure: 5.5yrs
- Compensation: €95.00k
Stefan Weber (54yo)
CEO & Executive Director
- Tenure: 7.3yrs
- Compensation: €647.00k
Ulrich Köstlin (67yo)
Non-Executive Chairman
- Tenure: 6.4yrs
- Compensation: €118.00k
Luca Benatti (58yo)
Non-Executive Director
- Tenure: 5.5yrs
- Compensation: €96.00k
Ze’ Seltzer
Member of Scientific & Clinical Advisory Board
- Tenure: 0yrs
Fabrizio Stocchi
Member of Scientific and Clinical Advisory Board
- Tenure: 0yrs
Emilio Perucca
Member of Scientific & Clinical Advisory Board
- Tenure: 0yrs
Paolo Marchettini
Member of Scientific & Clinical Advisory Board
- Tenure: 0yrs
Richard Murphy (55yo)
Chairman of the Board of Statutory Auditors
- Tenure: 12.4yrs
- Compensation: €13.00k
Company Information
Newron Pharmaceuticals S.p.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Newron Pharmaceuticals S.p.A.
- Ticker: NWRN
- Exchange: SWX
- Founded: 1998
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF105.823m
- Shares outstanding: 17.85m
- Website: https://www.newron.com
Number of Employees
Location
- Newron Pharmaceuticals S.p.A.
- Via Ludovico Ariosto 21
- Bresso
- Milan
- 20091
- Italy
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| NWRN | SWX (SIX Swiss Exchange) | Yes | Ordinary Shares | CH | CHF | Dec 2006 |
| NP5 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Dec 2006 |
| NWPH.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Dec 2006 |
| NP5 | XTRA (XETRA Trading Platform) | Yes | Ordinary Shares | DE | EUR | Dec 2006 |
| 0QOI | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | CHF | Dec 2006 |
Biography
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral ne ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/17 20:59 |
| End of Day Share Price | 2019/09/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.